Treatment options in hormone resistant prostate cancer

被引：4

作者：

De Mulder, PHM ^{[1
]}

Schalken, JA

Sternberg, CN

机构：

[1] Univ Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands

[2] Univ Med Ctr Nijmegen, Dept Urol, Nijmegen, Netherlands

[3] Fdn Vincenzo Pansodoro, Rome, Italy

来源：

ANNALS OF ONCOLOGY | 2002年 / 13卷

关键词：

D O I：

10.1093/annonc/mdf645

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：95 / 102

页数：8

共 70 条

[1]

ALBRECHT W, 1998, EUR UROL, V33, P47

[2]

BEER TM, 2000, P AN M AM SOC CLIN, V19, pA348

[3]

BERRY W, 2001, P AN M AM SOC CLIN, V20, pA175

[4]

Bonkhoff H, 1996, PROSTATE, V28, P98

[5] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].

Bubley, GJ ;

Carducci, M ;

Dahut, W ;

Dawson, N ;

Daliani, D ;

Eisenberger, M ;

Figg, WD ;

Freidlin, B ;

Halabi, S ;

Hudes, G ;

Hussain, M ;

Kaplan, R ;

Myers, C ;

Oh, W ;

Petrylak, DP ;

Reed, E ;

Roth, B ;

Sartor, O ;

Scher, H ;

Simons, J ;

Sinibaldi, V ;

Small, EJ ;

Smith, MR ;

Trump, DL ;

Vollmer, R ;

Wilding, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467

[6]

Chi KN, 2001, CLIN CANCER RES, V7, P3920

[7] Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials [J].

Dawson, NA .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3398-3405

[8] Phase II trial of GM-CSF in advanced prostate cancer [J].

Dreicer, R ;

See, WA ;

Klein, EA .

INVESTIGATIONAL NEW DRUGS, 2001, 19 (03) :261-265

[9]

DROZ JP, 1992, CANCER S, V71, P1123

[10] Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer [J].

Duque, JLF ;

Loughlin, KR ;

Adam, RM ;

Kantoff, PW ;

Zurakowski, D ;

Freeman, MR .

UROLOGY, 1999, 54 (03) :523-527

← 1 2 3 4 5 6 7 →